Data as of Jul 25, 2026 · Based on 2,718,867 AI responses across 9,511 prompts · See how Parse measures this
Hympavzihympavzi.com · Low evidenceHYMPAVZI (marstacimab-hncq) is a once-weekly fixed-dose pen for routine prophylaxis in patients 12 years and older with hemophilia A or B without inhibitors. It is injected under the skin and has demonstrated a 92% reduction in treated bleeds compared to on-demand factor-based treatment in clinical trials.
Parse Score